Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)

NCT01196091 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01196091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01196091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2010
Completion date
June 30, 2015
Enrollment
1,164 (actual)
Sites
192

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune disease, connective tissue disease, systemic lupus erythematosus